Charles River Laboratories International (NYSE:CRL) Upgraded at TD Cowen

TD Cowen upgraded shares of Charles River Laboratories International (NYSE:CRL) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning, Marketbeat Ratings reports. They currently have $179.00 price target on the medical research company’s stock.

Other research analysts also recently issued research reports about the company. Citigroup raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and lifted their price target for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. Barclays lifted their price target on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 8th. Evercore ISI raised Charles River Laboratories International from an “in-line” rating to an “outperform” rating and set a $170.00 price target for the company in a research note on Thursday, May 8th. Morgan Stanley cut their price target on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 5th. Finally, Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target for the company in a research note on Monday, March 3rd. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Charles River Laboratories International has a consensus rating of “Hold” and an average target price of $172.31.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $141.00 on Wednesday. The firm has a market capitalization of $6.93 billion, a P/E ratio of 940.00, a PEG ratio of 4.54 and a beta of 1.50. Charles River Laboratories International has a one year low of $91.86 and a one year high of $254.15. The company’s fifty day moving average is $135.43 and its two-hundred day moving average is $164.97. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping the consensus estimate of $2.06 by $0.28. The company had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business’s revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the firm earned $2.27 EPS. Analysts forecast that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the company’s stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the transaction, the executive vice president now owns 19,513 shares of the company’s stock, valued at $2,837,385.33. This represents a 2.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO James C. Foster acquired 6,075 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were bought at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the purchase, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. The trade was a 3.42% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 5,040 shares of company stock worth $807,407. Corporate insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Rothschild Investment LLC increased its stake in shares of Charles River Laboratories International by 480.0% during the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 144 shares during the last quarter. Brooklyn Investment Group increased its stake in shares of Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 86 shares during the last quarter. HM Payson & Co. acquired a new position in shares of Charles River Laboratories International during the 1st quarter valued at about $31,000. Pinnacle Bancorp Inc. increased its stake in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 65 shares during the last quarter. Finally, Optiver Holding B.V. acquired a new position in shares of Charles River Laboratories International during the 4th quarter valued at about $37,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).